RCAMU
PCRX icon

Rothschild & Co Asset Management US’s Pacira BioSciences PCRX Stock Holding History

Rothschild & Co Asset Management US’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-7,137
Closed -$244K – 563
2016
Q3 		$244K Buy
7,137
+175
+3% +$6.86K ﹤0.01% 522
2016
Q2 		$235K Buy
+6,962
New +$342K ﹤0.01% 548

Other funds holding PCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Rothschild & Co Asset Management US's PCRX Position: Q4 2016 in Review

Rothschild & Co Asset Management US sold out of Pacira BioSciences (PCRX) in Q4 2016, closing a stake of 7,137 shares — an estimated $244K sold.

Rothschild & Co Asset Management US first reported a position in PCRX in Q2 2016 and held it in 2 quarters. The position peaked at $244K in Q3 2016. 182 funds tracked by Wall St. Rank hold PCRX as of Q4 2016.

  • Rothschild & Co Asset Management US reported no remaining Pacira BioSciences position as of Q4 2016 after selling out during the quarter.
  • Rothschild & Co Asset Management US sold 7,137 Pacira BioSciences shares in Q4 2016, an estimated $244K.
  • Rothschild & Co Asset Management US first reported a position in Pacira BioSciences in Q2 2016 and held it in 2 quarters.
  • Rothschild & Co Asset Management US's Pacira BioSciences position peaked at $244K in Q3 2016.
  • 182 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2016.

Based on Rothschild & Co Asset Management US's 13F filing for Q4 2016, filed 15 Feb 2017.